Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
National Science Foundation manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are distributed across 2 distinct examiners but are located within 1 distinct art unit. This distribution shows that while the company's prosecution involves different individual reviewers, the subject matter remains concentrated within a single technical department.
SHALABY, AHMAD HUSSAM is the busiest examiner for this portfolio and is responsible for 1 busiest examiner pending action. The involvement of the distinct examiners within the art unit suggests that the Biotechnology & Pharmaceuticals filings are being reviewed by multiple people with similar technical expertise. Because there are 2 pending office actions in total, each action is currently being reviewed by a different individual within the same administrative unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, VU A | 1 | 92.4% | +6.6% |
| SHALABY, AHMAD HUSSAM | 1 | 0.0% | +0.0% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 58.1% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17770433 | MICRORNAS ENRICHED IN MEGAKARYOCYTIC EXTRACELLULAR VESICLES AND USES THEREOF | SULLIVAN, STEPHANIE LAUREN | 5d overdue |
| 18363319 | ORGANIC INFRARED PHOTODETECTION DEVICES UTILIZING AN INSULATIVE COMPONENT WITHIN THE ACTIVE LAYER | VU, VU A | — |
| 18205416 | SYSTEMS AND METHODS FOR A SYNTHETIC INFRASTRUCTURE MODEL FOR VULNERABILITY, FAILURE, AND FUTURE TRANSITION PLANNING | SHALABY, AHMAD HUSSAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17770433 | MICRORNAS ENRICHED IN MEGAKARYOCYTIC EXTRACELLULAR VESICLES AND USES THEREOF | SULLIVAN, STEPHANIE LAUREN | 5d overdue |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18363319 | ORGANIC INFRARED PHOTODETECTION DEVICES UTILIZING AN INSULATIVE COMPONENT WITHIN THE ACTIVE LAYER | VU, VU A | — | §103§112 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18205416 | SYSTEMS AND METHODS FOR A SYNTHETIC INFRASTRUCTURE MODEL FOR VULNERABILITY, FAILURE, AND FUTURE TRANSITION PLANNING | SHALABY, AHMAD HUSSAM | — | §101§103§112 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 17770433 | MICRORNAS ENRICHED IN MEGAKARYOCYTIC EXTRACELLULAR VESICLES AND USES THEREOF | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112 | Final Rejection | 5d overdue | Pending | Apr 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial